Proteomics

Dataset Information

0

The changes in cetuximab resistant HNSCC cell lines (e.g., OECM1-cetuximabR and CAL-27 cetuximabR) after being treated with Cetuximab (500 ug/ml) for at least 2 months. We used LC-MS/MS to identify the main phosphorylation sites in resistance cell lines.

ABSTRACT: Recent clinical trials revealed that prior use of Cetuximab may interfere with ICB efficacy. In this study, STAT1 protein levels changed after continued Cetuximab treatment (500 ug/ml). We used LC-MS/MS to compare the phosphorylation sites in wild-type and resistant cells. We proposed that the phosphorylation of STAT1 may lead to the degradation of the STAT1 protein.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

SUBMITTER: Po-Hsien Chiu  

LAB HEAD: Muh-Hwa Yang

PROVIDER: PXD054186 | Pride | 2025-12-29

REPOSITORIES: Pride

Json Xml

Dataset's files

Source:
Action DRS
20220120-A0664-01-TiO2-45_90ul-S4data-Gluc-4miss.mzML Mzml
20220120-A0664-01-TiO2-45_90ul-S4data-Gluc-4miss.mzid.gz Mzid
20220120-A0664-01-TiO2-45_90ul-S4data-Gluc-4miss.raw Raw
20220120-A0664-03-TiO2-45_90ul-S4data-Gluc-4miss.mzML Mzml
20220120-A0664-03-TiO2-45_90ul-S4data-Gluc-4miss.mzid.gz Mzid
Items per page:
1 - 5 of 7
altmetric image

Publications

Sequential cancer therapy presents a critical challenge, as the impact of prior treatments on immunotherapy remains unclear. Here, we demonstrate that therapeutic stress from prolonged cetuximab exposure induces tumor-intrinsic resistance to immune checkpoint blockade (ICB) in head and neck squamous cell carcinoma (HNSCC). In a multicenter analysis, extended cetuximab treatment correlates with poor ICB response and survival. Mechanistically, chronic therapeutic stress provokes an initial inflamm  ...[more]

Similar Datasets

Proteomics The changes in HNSCC cell lines (e.g., CAL-27 cetuximabR) after being treated with Cetuximab (500 ug/ml) for at least 2 months. We used LC-MS/MS to identify the main acetylation sites in resistance cell lines. In this study, it was found that the acetylation of STAT1 might hinder the downstream signaling of IFN-γ
2025-12-29 | PXD054332 | Pride
Proteomics The changes in HNSCC cell lines (e.g., OECM1) when treated with Cetuximab (500 ug/ml) at different passages. We used LC-MS/MS to identify the main target pathway. These findings could significantly enhance our evidence.
2025-12-29 | PXD054113 | Pride
Transcriptomics Genes expression in the different passages of OECM-1 cell line received cetuximab
2025-12-30 | GSE264007 | GEO
Transcriptomics Expression data of the cetuximab-resistant head and neck squamous cell lines and the parental cell lines.
2019-05-14 | GSE131108 | GEO
Proteomics Elizabethkingia anophelis Outer membrane vesicle proteomic, LC-MS/MS
2022-07-11 | PXD033416 | Pride
Transcriptomics Gene expression changes induced by dimerization of intracellular c-Mpl in cord blood CD34+ progenitors
2011-08-31 | E-GEOD-30585 | biostudies-arrayexpress
Transcriptomics Human colon cancer cell lines: NT(untreated) vs EGF, Cetuximab and Gefitinib treatments
2007-09-12 | GSE8967 | GEO
Proteomics Leukocyte analysis of proteomics in K74R mouse system
2023-03-02 | PXD037044 | Pride
Genomics Genes expression of OECM-1 and Cal-27 wild-type (WT) / cetuximab-resistant cell lines
| PRJNA1088830 | ENA
Transcriptomics Understanding molecular mechanisms of Cetuximab insensitivity in Colorectal Cancer (CRC)
2014-04-01 | E-GEOD-56386 | biostudies-arrayexpress